NDLI: Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.

Please wait, while we are loading the content...

Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin.

Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults.

A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.

Effects of injectable HPßCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.

Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5 -reductase inhibitor therapy and -blocker therapy: a retrospective analysis.

Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.

Drugs and trials: lessons from Plato.

Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.

Illegal 'no prescription' internet access to narrow therapeutic index drugs.

Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.

Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes.

Chemical sensitivity: pathophysiology or pathopsychology?

Atopic conditions in search of pathogenesis and therapy.

On top of atopy.

The relationship of autism and gluten.

Is a subtype of autism an allergy of the brain?

An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders.

Collaboration designed to increase translation of diabetes research outcomes into clinical practice.

Diabetes mellitus in the next decade: novel pipeline medications to treat hyperglycemia.

Inpatient management of diabetes and hyperglycemia.

Diabetes education: looking through the kaleidoscope.

Year: 2013 Volume: 35 Issue: 4

Year: 2013 Volume: 35 Issue: 3

Year: 2013 Volume: 35 Issue: 2

Year: 2013 Volume: 35 Issue: 1

Year: 2012 Volume: 34

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Braun, Sebastian Russo, Leo Zeidler, Jan Linder, Roland Hodgkins, Paul
Spatial Coverage	Germany
Description	Country affiliation: Germany Author Affiliation: Braun S ( Herescon GmbH, Health Economic Research & Consulting, Hannover, Germany. braun@herescon.com)
Abstract	BACKGROUND: Attention deficit/hyperactivity disorder (ADHD) is a heterogeneous behavioral disorder commonly found in children, with serious lifetime health and social consequences for both children and their parents. Public awareness of ADHD in Germany has increased in the past decade, but little is known about the costs of treating newly diagnosed patients in clinical practice. OBJECTIVE: This study aimed to describe the resource utilization and treatment costs of patients aged 6 to 17 years with newly diagnosed ADHD, using patient data from a German sickness fund, and to quantify resource utilization by drug treatment and treatment persistence. METHODS: To identify patients with newly diagnosed ADHD, the second largest German sickness fund was utilized. Complete claims data of all de-identified patients meeting eligibility criteria for 2007 and 2008 were extracted. Patients were divided into 1 of 3 treatment groups: drug treatment-persistent, drug treatment-nonpersistent, and nondrug treatment. The differences in costs and resource utilization are reported in a descriptive manner, with paired and unpaired 2-sample Wilcoxon tests used. RESULTS: Of 3407 newly diagnosed patients with ADHD, 1105 (32%) received an ADHD-specific drug following diagnosis; the remaining 2302 comprised the nondrug treatment group. Of the total number of drug-treated patients, 1-year observational data were available for only 786 methylphenidate users (71%). Of these, 503 patients (64%) comprised the drug treatment-persistent group (those having at least 1 prescription every 3 months during the 12 months following their first ADHD prescription) and 283 (36%) comprised the drug treatment-nonpersistent group. After excluding those patients with <12 months of follow-up, 1779 patients (52%) were included in the nondrug-treatment group. Outpatient visits and the number of drug prescriptions and associated costs were highest in the drug treatment-persistent group (P = 0.05); however, the number of hospital admissions and days spent in-hospital were lowest in this group. Significant average savings of 187/y in overall costs (P = 0.05) were noted for the drug treatment-persistent group compared with the drug treatment-nonpersistent group. These mean savings were 739/y and 552/y (drug treatment-persistent group and drug treatment-nonpersistent group, respectively) compared with nondrug-treated patients. CONCLUSIONS: There are potential cost-savings benefits when patients are treatment persistent. Therefore, future disease-management programs might consider treatment persistence as potentially reducing overall payer costs. Additionally, the clinical and psychosocial situations of patients and their families should be taken into account.
File Format	HTM / HTML
ISSN	01492918
Issue Number	5
Volume Number	35
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2013-05-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Attention Deficit Disorder With Hyperactivity Drug Therapy Central Nervous System Stimulants Therapeutic Use Medication Adherence Methylphenidate Adolescent Economics Administration & Dosage Child Cost Savings Databases, Factual Female Follow-up Studies Germany Health Care Costs Statistics & Numerical Data Health Services Utilization Humans Male Statistics, Nonparametric Comparative Study Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

'Descriptive Comparison of Drug Treatment-Persistent, - Nonpersistent, and Nondrug Treatment Patients With Newly Diagnosed Attention Deficit/Hyperactivity Disorder in Germany' Clin Ther 2013;35:673-685. : Corrigendum

An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder.

Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.

Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.

Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults.

An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom.

Debate is needed over who provides drug treatment in attention deficit hyperactivity disorder.

OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.

Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD.

Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.

Similar Documents

'Descriptive Comparison of Drug Treatment-Persistent, - Nonpersistent, and Nondrug Treatment Patients With Newly Diagnosed Attention Deficit/Hyperactivity Disorder in Germany' Clin Ther 2013;35:673-685. : Corrigendum

An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder.

Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.

Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.

Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults.

An observational study of pharmacological treatment in primary care of children with ADHD in the United kingdom.

Debate is needed over who provides drug treatment in attention deficit hyperactivity disorder.

OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.

Neuroimaging markers for the prediction of treatment response to Methylphenidate in ADHD.

Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.